•
Helixworks Technologies • 4m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See MoreDownload the medial app to read full posts, comements and news.